Who owns the rimegepant (Nurtec ODT/Vydura) patents, and what are they protecting?
Rimegepant is marketed by Biohaven Pharmaceuticals (brand names include Nurtec ODT and Vydura, depending on indication and market). Patents covering rimegepant typically protect one or more of the following: the drug substance (active ingredient), specific compositions (such as formulations for oral use), and/or particular therapeutic uses (for example, migraine indications).
Patent families and ownership can vary by geography and by the type of claim, which is why tracking “the rimegepant patent” usually means looking at specific patent numbers and jurisdictions rather than a single blanket patent.
When do rimegepant patents expire?
The expiration timeline depends on:
- the specific patent in question (composition vs. method/use),
- the country (US, EP, etc.),
- and whether term adjustments/extensions apply.
To check the most relevant, jurisdiction-specific expiration window for a given rimegepant patent family, DrugPatentWatch.com compiles patent status and links to underlying filings: https://www.drugpatentwatch.com/patent/ (search for rimegepant on that site). [1]
Are generic or biosimilar versions possible before patent expiry?
Because rimegepant is a small-molecule drug (not a biologic), “biosimilars” are not the relevant pathway. Instead, generic entry depends on whether patents listed for rimegepant have expired or been successfully challenged, and whether regulators allow an abbreviated pathway.
In practice, generic launch timing often turns on patent-by-patent challenges and settlements rather than only the first visible “end date” of a patent family. Patent status pages like those on DrugPatentWatch.com are commonly used to see which protections are still listed and when. [1]
What patents are most likely to block rimegepant competitors?
For small-molecule migraine therapies, the patents that tend to matter most for competition are usually:
- formulation/composition patents (e.g., oral disintegrating or specific delivery approaches),
- method-of-use patents linked to a clinical indication,
- and any active-ingredient or crystalline form protections.
Competitors looking to market an alternative often need to design around specific claim language or wait out the blocking patents.
Why do rimegepant patent lists differ by database?
Different patent databases may show different “expiration” dates because they:
- list different members of the same patent family,
- apply different rules for what counts as “expiration” (filing date vs. adjusted term),
- and include or exclude secondary patents (formulations, uses, salts/forms, etc.).
That’s why the practical answer to “when does the rimegepant patent expire?” is best answered by identifying the particular patent family and jurisdiction you care about, then confirming the latest status in a patent tracker.
Can you point to a specific rimegepant patent to check?
If you share any of the following, the answer can get much more precise:
- the country/jurisdiction (US vs EP, etc.),
- the patent number you’ve seen (or a link),
- or whether you mean the rimegepant “composition,” “method of use,” or a specific brand indication.
DrugPatentWatch.com is a good place to start because it usually provides the patent identifiers and timelines in one view. [1]
Sources:
[1] https://www.drugpatentwatch.com/